Skip to content

US · ABUS · BIOTECHNOLOGY

Arbutus Biopharma Corp (ABUS) intrinsic value and stock valuation

$4.02as of 2026-11-21 · Mkt cap 912.62M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Arbutus Biopharma Corp DCF and intrinsic value

InvestorsCraft values ABUS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ABUS’s statements →

Arbutus Biopharma Corp Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Warminster, PA 18974 arbutusbio.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$14.1M+15.3% 5y CAGRd
20112025
Net income
-$-33.5M
20112025
Free cash flow
-$-39.64M
20112025
Total equity
$76.6M-5.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$14.1M$6.17M$18.1M$39M$11M
Operating income-$-27.05M-$-76.32M-$-78.1M-$-65.46M-$-73.52M
Net income-$-33.5M-$-69.92M-$-72.85M-$-69.46M-$-76.25M
EPSd-$-174.84K-$-376.7K-$-438.96K-$-460.18K-$-717.71K
Operating cash flow-$-39.64M-$-64.85M-$-85.94M-$-35.36M-$-67.53M
Capital expenditure$0.00-$-180K-$-1.01M-$-510K-$-810K
Free cash flow-$-39.64M-$-65.03M-$-86.94M-$-35.87M-$-68.34M
Total assets$94.6M$131.7M$144.4M$195.4M$204.5M
Total debt$4.19M$6.12M$8.72M$12.6M$18.9M
Net debt-$-13.82M-$-30.21M-$-17.56M-$-18.22M-$-90.37M
Total equity$76.6M$97.4M$106M$136.9M$169.4M
Cash and short-term investments$91.5M$122.6M$126M$146.9M$155.3M
Income statement
20252024202320222021
Revenue$14.1M$6.17M$18.1M$39M$11M
Cost of revenue$360K$0.00$0.00$0.00$0.00
Gross profit$13.7M$6.17M$18.1M$39M$11M
Research and development expenses$25.2M$54M$73.7M$84.4M$65.5M
Selling, general and administrative expenses$15.9M$22.1M$22.5M$17.8M$17.1M
Other expenses-$-360K$6.34M$70K$2.23M$1.87M
Operating expenses$40.8M$82.5M$96.2M$104.5M$84.5M
Cost and expenses$41.1M$82.5M$96.2M$104.5M$84.5M
Interest income$4.07M$6.58M$5.69M$2.19M$130K
Interest expense$100K$140K$460K$1.73M$2.86M
Depreciation and amortization$360K$1.38M$1.4M$1.43M$1.75M
Ebitda-$-33.04M-$-68.4M-$-70.99M-$-61.86M-$-71.64M
Operating income-$-27.05M-$-76.32M-$-78.1M-$-65.46M-$-73.52M
Total other income/expenses, net-$-6.45M$6.4M$5.25M$440K-$-2.73M
Income before tax-$-33.5M-$-69.92M-$-72.85M-$-65.01M-$-76.25M
Income tax expense$0.00$0.00$0.00$4.44M$0.00
Net income-$-33.5M-$-69.92M-$-72.85M-$-69.46M-$-76.25M
Weighted average shares outstanding$191.6M$185.6M$166M$150.9M$106.2M
Weighted average diluted shares outstanding$191.6M$185.6M$166M$150.9M$106.2M
Balance sheet
20252024202320222021
Cash and short-term investments$91.5M$122.6M$126M$146.9M$155.3M
Net receivables$1.75M$2.41M$1.78M$1.35M$900K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$94.5M$127.3M$132M$151.1M$160.7M
Property, plant and equipment, net$30K$4.36M$6.09M$6.81M$8.07M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$6.28M$37.4M$35.7M
Total non-current assets$160K$4.39M$12.4M$44.3M$43.8M
Total assets$94.6M$131.7M$144.4M$195.4M$204.5M
Accounts payable$1.17M$2.32M$3.22M$3.52M$3.17M
Short-term debt$550K$480K$420K$370K$380K
Deferred revenue$0.00$7.57M$11.8M$16.5M$0.00
Total current liabilities$6.01M$15.6M$22.5M$32.9M$11.2M
Long-term debt$3.64M$5.63M$8.3M$12.2M$18.5M
Deferred revenue, non-current$0.00$2.86M$0.00$6M$0.00
Total non-current liabilities$12M$18.7M$15.9M$25.7M$23.8M
Capital lease obligations$200K$810K$1.77M$1.81M$2.23M
Total liabilities$18M$34.3M$38.4M$58.6M$35.1M
Common stock$1.42B$1.41B$1.35B$1.32B$1.29B
Retained earnings-$-1.38B-$-1.35B-$-1.28B-$-1.2B-$-1.13B
Accumulated other comprehensive income (loss)-$-48.1M-$-48.13M-$-48.42M-$-50.49M-$-48.33M
Total equity$76.6M$97.4M$106M$136.9M$169.4M
Total investments$73.5M$86.3M$106M$153.5M$81.7M
Total debt$4.19M$6.12M$8.72M$12.6M$18.9M
Net debt-$-13.82M-$-30.21M-$-17.56M-$-18.22M-$-90.37M
Cash flow statement
20252024202320222021
Net income-$-33.5M-$-69.92M-$-72.85M-$-69.46M-$-76.25M
Depreciation and amortization$360K$1.38M$1.4M$1.43M$1.75M
Stock-based compensation$6.95M$8.99M$9.3M$7.18M$6.42M
Change in working capital-$-10.02M-$-2.83M-$-18.23M$29.2M$930K
Accounts receivable$1.38M-$-630K-$-420K-$-450K$410K
Inventory$0.00$0.00$0.00$0.00-$-1.91M
Accounts payable-$-2.1M$0.00$0.00$5.22M$1.91M
Net cash provided by operating activities-$-39.64M-$-64.85M-$-85.94M-$-35.36M-$-67.53M
Investments in property, plant and equipment$0.00-$-180K-$-1.01M-$-510K-$-810K
Acquisitions, net$0.00$0.00$0.00$0.00$1.81M
Net cash used for investing activities$15.6M$23M$50.8M-$-74.94M-$-12.68M
Common stock issued$5.72M$44.1M$29.9M$20.3M$134.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00-$-12.14M
Net cash used for financing activities$5.72M$52M$30.7M$31.8M$137.2M
Net change in cash-$-18.32M$10M-$-4.49M-$-78.51M$57M
Cash at end of period$18M$36.3M$26.3M$30.8M$109.3M
Operating cash flow-$-39.64M-$-64.85M-$-85.94M-$-35.36M-$-67.53M
Capital expenditure$0.00-$-180K-$-1.01M-$-510K-$-810K
Free cash flow-$-39.64M-$-65.03M-$-86.94M-$-35.87M-$-68.34M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Arbutus Biopharma Corp

        Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

        CEO
        Lindsay Androski
        Employees
        19
        Beta
        0.62

        Explore

        Frequently asked questions

        What is the intrinsic value of Arbutus Biopharma Corp (ABUS)?

        Arbutus Biopharma Corp (ABUS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ABUS undervalued?

        ABUS trades at a price of $4.02 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.